Dossier assessment
Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen, without resistance to, and no virological failure with non-nucleoside reverse transcriptase inhibitors (NNRTIs) or integrase inhibitors (INIs)
Added benefit not proven.
Project details
- Project no.
- A21-47
- Commission
- Commission awarded on 03.05.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Cabotegravir (HIV-1 infection in adolescents) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed